HK33691A - Medical composition for external application - Google Patents

Medical composition for external application

Info

Publication number
HK33691A
HK33691A HK336/91A HK33691A HK33691A HK 33691 A HK33691 A HK 33691A HK 336/91 A HK336/91 A HK 336/91A HK 33691 A HK33691 A HK 33691A HK 33691 A HK33691 A HK 33691A
Authority
HK
Hong Kong
Prior art keywords
carbon atoms
sub
independently represent
phosphate
hydrocarbon group
Prior art date
Application number
HK336/91A
Other languages
German (de)
English (en)
French (fr)
Inventor
Kenji Hara
Hiromichi Takahashi
Tetsuro Kamiya
Kaoru Tsujii
Original Assignee
Kao Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corporation filed Critical Kao Corporation
Publication of HK33691A publication Critical patent/HK33691A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK336/91A 1984-10-11 1991-05-02 Medical composition for external application HK33691A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59213152A JPS6191137A (ja) 1984-10-11 1984-10-11 外用薬剤組成物

Publications (1)

Publication Number Publication Date
HK33691A true HK33691A (en) 1991-05-10

Family

ID=16634426

Family Applications (1)

Application Number Title Priority Date Filing Date
HK336/91A HK33691A (en) 1984-10-11 1991-05-02 Medical composition for external application

Country Status (7)

Country Link
US (1) US4686211A (enExample)
EP (1) EP0179277B1 (enExample)
JP (1) JPS6191137A (enExample)
DE (1) DE3565937D1 (enExample)
ES (1) ES8701683A1 (enExample)
HK (1) HK33691A (enExample)
MY (1) MY100022A (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01151516A (ja) * 1987-12-08 1989-06-14 Shionogi & Co Ltd ビタミンｅ配合外用剤
GB8828018D0 (en) * 1988-12-01 1989-01-05 Unilever Plc Topical composition
GB8828014D0 (en) * 1988-12-01 1989-01-05 Unilever Plc Topical composition
GB8828020D0 (en) * 1988-12-01 1989-01-05 Unilever Plc Topical composition
GB8828017D0 (en) * 1988-12-01 1989-01-05 Unilever Plc Topical composition
GB8828013D0 (en) * 1988-12-01 1989-01-05 Unilever Plc Topical composition
US4906454A (en) * 1989-02-23 1990-03-06 The Procter & Gamble Company Deodorant compositions containing specific piroctone salts and perfumes
US5262165A (en) * 1992-02-04 1993-11-16 Schering Corporation Transdermal nitroglycerin patch with penetration enhancers
GB9003199D0 (en) * 1990-02-13 1990-04-11 Unilever Plc Topical composition
US5565207A (en) * 1990-09-19 1996-10-15 Pola Kasei Kogyo Kabushiki Kaisha Scalp moisturizer and external skin preparation
GB9101986D0 (en) * 1991-01-30 1991-03-13 Smith & Nephew Pharmaceutical compositions
US5409911A (en) * 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
TW251302B (enExample) * 1992-12-28 1995-07-11 Kao Corp
US5665742A (en) * 1994-05-31 1997-09-09 Kao Corporation Bath medicine composition and its use in inhibiting the generation of body odor
US5543430A (en) * 1994-10-05 1996-08-06 Kaesemeyer; W. H. Method and formulation of stimulating nitric oxide synthesis
US5968983A (en) * 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US6239172B1 (en) * 1997-04-10 2001-05-29 Nitrosystems, Inc. Formulations for treating disease and methods of using same
US5560913A (en) * 1995-01-27 1996-10-01 The Procter & Gamble Company Pharmaceutical compositions
US6605751B1 (en) * 1997-11-14 2003-08-12 Acrymed Silver-containing compositions, devices and methods for making
US6426093B1 (en) * 1998-02-09 2002-07-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Synergistic biocidal activity if ternary complexes of negatively-charged biocides (component A), transition metal ions (component B), and neutral chelators (component C)
US5972920A (en) * 1998-02-12 1999-10-26 Dermalogix Partners, Inc. Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders
US6121253A (en) * 1998-11-20 2000-09-19 Merck Frosst Canada & Co. Prostaglandin conjugates for treating or preventing bone disease
US6254294B1 (en) * 1999-08-09 2001-07-03 Sigrid G. Muhar Pharmaceutical kit
FR2799369B1 (fr) * 1999-10-08 2001-12-21 Oreal Association d'escine et de sulfate de dextran et son utilisation
US8679523B2 (en) 1999-12-30 2014-03-25 Kimberly-Clark Worldwide, Inc. Oxygen-delivery closed cell foam matrix for wound treatment
US7758888B2 (en) * 2000-04-21 2010-07-20 Sol-Gel Technologies Ltd. Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
KR100612398B1 (ko) * 2000-11-14 2006-08-16 바이탈 헬스 사이언시즈 피티와이 리미티드 포스페이트 유도체의 착체
AUPR549901A0 (en) * 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
EP1254909A1 (de) * 2001-04-30 2002-11-06 Cognis Iberia, S.L. Phosphorsäureester
AU2002317053B2 (en) * 2001-07-27 2004-08-05 Vital Health Sciences Pty Ltd Dermal therapy using phosphate derivatives of electron transfer agents
BR0215102A (pt) * 2001-12-13 2004-11-03 Vital Health Sciences Pty Ltd Transporte transdermal de compostos, formulação tópica, método para melhorar a absorção da pele, método para a terapia de reposição hormonal, uso de um ou mais derivados de fosfato de um composto hidróxi farmacêutico em um sistema de aplicação transdermal, sistema de aplicação transdermal, método para aplicação de um composto hidróxi farmacêutico a um indivìduo e para melhorar a eficácia de uma formulação
US6833139B1 (en) * 2002-01-09 2004-12-21 Ferndale Laboratories, Inc. Composition and method for the treatment of anorectal disorders
US8486426B2 (en) * 2002-07-29 2013-07-16 Kimberly-Clark Worldwide, Inc. Methods and compositions for treatment of dermal conditions
AU2002950713A0 (en) * 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
BRPI0406484A (pt) * 2003-01-17 2005-12-06 Vital Health Sciences Pty Ltd Método de inibição da ocorrência de uma ou mais das seguintes condições: a proliferação de monócitos/macrófagos; ou a proliferação de células do músculo liso; ou a expressão de receptores de cd36; ou a absorção de lipoproteìna de baixa densidade - ldl oxidada, método de alìvio de sintomas de tratamento ou prevenção de aterosclerose; de diabetes; do mal de alzheimer, método de inibição da ocorrência da formação de placas no sistema vascular, método de alìvio da inflamação associada a ocorrência de uma ou de mais das seguintes condições: a proliferação de monócitos, a proliferação de células do músculo liso, a expressão de ldl oxidadas ou de receptor descontaminante, composição farmacêutica, uso de uma quantidade eficaz de um ou mais derivados ou fosfato de um ou mais agentes de transferência de elétrons conjuntamente com um veìculo ou um diluente apropriado, uso de uma quantidade eficaz de um ou mais derivados de fosfato de (alfa)-tocoferol conjuntamente com um veìculo ou um diluente apropriado e uso de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais agentes de transferência de elétrons selecionados do grupo que consiste em fosfato mono-tocoferila, fosfato de di-tocoferila e as misturas destes conjuntamente com um veìculo ou um diluente apropriado
AU2003901815A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
CA2557354C (en) 2004-03-03 2013-05-07 Vital Health Sciences Pty Ltd. Alkaloid formulations
US20050282870A1 (en) * 2004-06-16 2005-12-22 Carter Stephen G Peripherally-acting vasodilators
BRPI0513967A (pt) * 2004-07-30 2008-05-20 Acrymed Inc composições de prata antimicrobianas
US8361553B2 (en) 2004-07-30 2013-01-29 Kimberly-Clark Worldwide, Inc. Methods and compositions for metal nanoparticle treated surfaces
EP1781098B1 (en) * 2004-07-30 2015-10-07 Avent, Inc. Antimicrobial devices and compositions
US9289378B2 (en) * 2004-09-20 2016-03-22 Avent, Inc. Antimicrobial amorphous compositions
WO2006092024A1 (en) * 2005-03-03 2006-09-08 Vital Health Sciences Pty Ltd Compounds having anti-cancer properties
MX2007015949A (es) * 2005-06-17 2008-03-07 Vital Health Sciences Pty Ltd Un vehiculo que comprende uno o mas derivados de fosfato de di- y/o mono-(agentes de transferencia de electrones) o complejos de los mismos.
AU2006274541B2 (en) 2005-08-02 2012-12-13 Sol-Gel Technologies Ltd. Metal oxide coating of water insoluble ingredients
WO2007070981A1 (en) * 2005-12-23 2007-06-28 Vital Health Sciences Pty Ltd Compounds having cytokine modulating properties
EP2015722B1 (en) * 2006-04-28 2016-11-16 Avent, Inc. Antimicrobial site dressings
BRPI0808163A2 (pt) 2007-02-01 2014-11-04 Sol Gel Technologies Ltd Composição para aplicação tópica, métodos para tratar uma condição de superfície em um indivíduo, para preparar uma composição, e para usar o kit, e, kit
KR20090121291A (ko) * 2007-02-01 2009-11-25 솔-겔 테크놀로지스 리미티드 산화금속 코팅을 포함한 입자의 제조방법 및 산화금속 코팅을 포함한 입자
JP2010235523A (ja) * 2009-03-31 2010-10-21 Kao Corp 水性毛髪洗浄剤
US10071030B2 (en) 2010-02-05 2018-09-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
JP5806287B2 (ja) 2010-03-30 2015-11-10 フォスファジェニクス リミティド 経皮送達パッチ
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
US9687465B2 (en) 2012-11-27 2017-06-27 Sol-Gel Technologies Ltd. Compositions for the treatment of rosacea
MX383940B (es) 2015-12-09 2025-03-14 Phosphagenics Ltd Formulación farmacéutica que contiene tocol fosfato.
JP7198754B2 (ja) 2016-12-21 2023-01-04 アベーチョ バイオテクノロジー リミテッド 方法
WO2019012537A1 (en) 2017-07-12 2019-01-17 Sol-Gel Technologies Ltd COMPOSITIONS COMPRISING ENCAPSULATED TRETTINOIN
JP2019043853A (ja) * 2017-08-30 2019-03-22 旭化成株式会社 経皮吸収促進剤、経皮吸収促進助剤、及び経皮製剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046886A (en) * 1975-01-17 1977-09-06 The Procter & Gamble Company Dermatological compositions
US4130667A (en) * 1976-01-12 1978-12-19 The Procter & Gamble Company Dermatological compositions

Also Published As

Publication number Publication date
US4686211A (en) 1987-08-11
MY100022A (en) 1989-04-20
JPH0469129B2 (enExample) 1992-11-05
DE3565937D1 (en) 1988-12-08
ES8701683A1 (es) 1986-12-01
ES547738A0 (es) 1986-12-01
EP0179277B1 (en) 1988-11-02
JPS6191137A (ja) 1986-05-09
EP0179277A1 (en) 1986-04-30

Similar Documents

Publication Publication Date Title
EP0179277B1 (en) Medical composition for external application
US4895727A (en) Pharmaceutical vehicles for exhancing penetration and retention in the skin
US7387789B2 (en) Transdermal delivery of non-steroidal anti-inflammatory drugs
US6923983B2 (en) Transdermal delivery of hormones
KR100952786B1 (ko) 제약 조성물
US8486375B2 (en) Foamable compositions
DE69524614T2 (de) Arzneimittelbestandteile einschliesslich eines n-substituierten o-toluidinderivats und transdermal absorbierbare zubereitung
CA1238275A (en) Menthol enhancement of transdermal drug delivery
ES2624557T3 (es) Composiciones farmacéuticas transdérmicas que comprenden un SERM
EP0055029A2 (en) Preparations for the treatment of dermatoses
JPH10502355A (ja) Ｎ−アセチル−ｌ−システインを含んだ局所組成物
JPH0244815B2 (enExample)
JP2540294B2 (ja) 経皮吸収製剤
WO1988003799A1 (en) Pharmaceutical vehicles for reducing transdermal flux
JP3313891B2 (ja) 経皮吸収促進剤及び皮膚外用剤
EA007351B1 (ru) Фармацевтическая композиция для чрескожной доставки физиологически активных агентов
JPH03120230A (ja) 薬効成分の経皮吸収促進剤及び経皮吸収型製剤
JPH0617316B2 (ja) 経皮吸収製剤
JPH0566930B2 (enExample)
JPH0621061B2 (ja) 尿素を安定に含む透明ゲル製剤
JP3522832B2 (ja) 経皮吸収促進剤及び皮膚外用剤
JPH08143474A (ja) 経皮吸収促進剤
JPH0611716B2 (ja) 経皮吸収促進剤
JP3313890B2 (ja) 経皮吸収促進剤及び皮膚外用剤
JPH11147826A (ja) 経皮吸収性の向上方法及び皮膚外用剤

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)